These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 27342566)

  • 1. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
    Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
    Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
    Yang CY; Lin MW; Chang YL; Wu CT
    Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
    Liu Y; Wu A; Li X; Wang S; Fang S; Mo Y
    Asian J Surg; 2022 Jan; 45(1):367-375. PubMed ID: 34325991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.